Eagle Strategies LLC Gilead Sciences, Inc. Transaction History

Eagle Strategies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	SELL	$63.15 - $72.88 $9,409 - $10,859	-149 Reduced 4.66%	3,050 $209,000
Q1 2024 Apr 22, 2024	BUY	$71.58 - $87.29 $9,520 - $11,609	133 Added 4.34%	3,199 $234,000
Q4 2023 Jan 26, 2024	BUY	$73.27 - $83.09 $3,150 - $3,572	43 Added 1.42%	3,066 $248,000
Q3 2023 Nov 07, 2023	BUY	$73.94 - $80.67 $4,288 - $4,678	58 Added 1.96%	3,023 $226,000
Q2 2023 Aug 02, 2023	BUY	$76.01 - $86.7 $304 - $346	4 Added 0.14%	2,965 $228,000
Q1 2023 Apr 21, 2023	BUY	$77.31 - $88.08 $309 - $352	4 Added 0.14%	2,961 $245,000
Q4 2022 Feb 03, 2023	BUY	$62.32 - $89.47 $184,280 - $264,562	2,957 New	2,957 $253,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Eagle Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Eagle Strategies LLC with notifications on news.